Target intelligence / Profile preview

Bacterial ribosome–SpeFL complex (None formally established; sometimes referenced as "ribosome–SpeFL" or "SpeFL–ribosome complex")

Target
None formally established; sometimes referenced as "ribosome–SpeFL" or "SpeFL–ribosome complex"
Molecular classification
Ribosome (molecular machine; ribonucleoprotein complex), Regulatory nascent peptide (SpeFL), Other (metabolic sensor complex)
01

Overview

The bacterial ribosome–SpeFL complex refers to a regulatory state formed when ornithine is captured by the translating bacterial ribosome, causing stalling during translation of the nascent peptide SpeFL. SpeFL is a sensor peptide that binds ornithine in a highly selective manner, forming a compact fold that obstructs the ribosomal exit tunnel and blocks release factor activity. This stalling promotes transcriptional antitermination and upregulates the expression of the polyamine biosynthetic enzyme ornithine decarboxylase (SpeF), thereby increasing polyamine synthesis. The system is found in γ-proteobacteria and plays a crucial role in adaptation, stress response, and microbial virulence. The structure has been resolved by cryo-electron microscopy, revealing the molecular details of ornithine sensing and peptide-ribosome interaction. This complex is not a classical drug target but provides insight into bacterial metabolic regulation and potential strategies for antimicrobial intervention.

Other names
Ribosome–SpeFL complexSpeFL-stalled ribosomeOrnithine sensing ribosome–SpeFL complex
02

Mechanism of action

Not applicable to the SpeFL complex directly; antibiotic mechanisms for ribosome include inhibition of protein synthesis (ribosome inhibition).

03

Biological functions

Regulation of polyamine synthesis (cell growth, stress response, virulence)Ornithine sensingTranscription antitermination via ribosome stalling
04

Disease associations

Infection (relevant for bacterial virulence, but not a direct disease target)
05

Safety considerations

None directly regarding the SpeFL complex.Broad-spectrum antibiotics targeting the ribosome can affect microbiota and cause side effects, but this does not relate specifically to the SpeFL-ornithine sensing interaction.
06

Interacting drugs

None specific to the SpeFL complex.

2 more in the full profile.

07

Biomarkers

None established for patient selection or efficacy monitoring; not used clinically.

Beyond the preview

Go deeper on Bacterial ribosome–SpeFL complex (None formally established; sometimes referenced as "ribosome–SpeFL" or "SpeFL–ribosome complex").

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bacterial ribosome–SpeFL complex (None formally established; sometimes referenced as "ribosome–SpeFL" or "SpeFL–ribosome complex").

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call